Hemispherx Biopharma Inc. may have to hang its hat on the unmet medical need in chronic fatigue syndrome if it is to have any hope of a positive advisory committee review of Ampligen (rintatolimod) given FDA staff’s overwhelmingly negative efficacy and safety evaluation.
In briefing documents released ahead of the Arthritis Advisory Committee’s Dec
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?